ScripThe second half of this year could bring two major new approvals for Boehringer Ingelheim, with lung cancer drug zongertinib and idiopathic pulmonary fibrosis candidate nerandomilast both currently un
Pink SheetThe US Food and Drug Administration’s approval decisions for novel agents will come from different divisions in the second half of 2025, compared to the first half, the Pink Sheet ’s US FDA Performan
ScripBayer AG has been touting Kerendia (finerenone) as a blockbuster sales product in both kidney and cardiovascular disease for several years, and a July 14 US Food and Drug Administration approval for
Pink SheetWith 22 novel agents approved in the first six months of 2025, the US FDA is already behind its average approval count for the first half of the year, and the user fee calendar for the second half doe